DRIP Score for Drug-Resistant Pneumonia
Drug Resistance in Pneumonia (DRIP) score (Webb 2016): identifies patients with community-onset pneumonia at risk of a drug-resistant pathogen. Score ≥ 4 indicates high risk.
Score interpretation
DRIP <4 — low risk of drug-resistant pathogen. Standard CAP pathogens likely.
→ Standard CAP antibiotic regimen (beta-lactam ± macrolide or fluoroquinolone alone); no need for MRSA/Pseudomonas coverage
DRIP ≥4 — high risk of drug-resistant organism
→ Broad-spectrum coverage: anti-MRSA agent (vancomycin, linezolid) PLUS anti-pseudomonal beta-lactam; de-escalate based on culture results
Interpretation bands for the DRIP Score. Apply clinical judgement and local guidance.
References
- Webb BJ, Dascomb K, Stenehjem E, et al. Derivation and multicenter validation of the Drug Resistance in Pneumonia clinical prediction score. Antimicrob Agents Chemother. 2016;60(5):2652–2663.
Related
Curated clinical cross-links plus same-class fallbacks.
- Pneumonia Severity Index (PSI/PORT) · Pneumonia
- CRB-65 Score for Community Pneumonia · Pneumonia
- SMART-COP Score for Pneumonia Severity · Pneumonia
- CURB-65 Score for Community-Acquired Pneumonia · Pneumonia
- MuLBSTA Score for Viral Pneumonia Mortality · Pneumonia
- SCAP Score for Severe Community-Acquired Pneumonia · Pneumonia
- Linezolid · Oxazolidinone — MRSA / VRE / Drug-Resistant TB (adjunct)
- Linezolid (Burns — Vancomycin-Resistant/Refractory MRSA) · Antibiotic — Oxazolidinone
- Flucloxacillin · Antibiotic — Penicillinase-Resistant
- Flucloxacillin · Antibiotic (Penicillinase-Resistant Penicillin)
- Teicoplanin · Glycopeptide Antibiotic — MRSA / Gram-Positive Infections
- Amikacin · Aminoglycoside — Drug-Resistant Gram-Negative / MDR-TB
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.